• Nanobiotix soars as late-phase cancer trial hits endpoint fiercebiotech
    June 25, 2018
    A phase 2/3 trial of Nanobiotix’s NBTXR3 in soft tissue sarcoma has met (PDF) its primary endpoint. The top-line success against the pathological complete response rate endpoint sent Nanobiotix’s stock up by more than 50%.
PharmaSources Customer Service